Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
Hematology
; 28(1): 2207946, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-37183912
ABSTRACT
BACKGROUND:
No consensus has been reached yet concerning treatment strategies for a sequential classic Hodgkin lymphoma (CHL) following gray zone lymphoma (GZL). Prognosis of GZL after a failed autologous hematopoietic stem-cell transplantation (auto-HCT) is poor and treatment strategy is very limited. As yet there are limited data showing clinical outcomes of brentuximab vedotin (BV) for GZL, especially for sequential CHL after GZL. CASE PRESENTATION We report a case of CHL following primary refractory GZL after a failed auto-HCT and showed favorable response to first-line CHL-directed chemoradiotherapy consisting of BV plus doxorubicin, vinblastine, and dacarbazin (AVD) followed by irradiation. The sequential cases with an early evolution, whose diagnosis of second lymphoma was made within a year, have been recently reported very poor survival shorter than a year. Whether a sequential CHL following GZL should be treated as a primary or relapsed disease has not been clearly elucidated. Our patient showed favorable response to first-line CHL-directed chemoradiotherapy without allogenic hematopoietic stem-cell transplantation and has in continuous remission for 2 years.CONCLUSIONS:
The management of our case could help for physicians to make better treatment decisions and provide insights for further exploration in future studies.Palabras clave
BV+AVD, brentuximab vedotin doxorubicin, vinblastine, and dacarbazin; CHL, classic Hodgkin lymphoma; FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography-computed tomography; GZL, Gray zone lymphoma; Gray zone lymphoma; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone; brentuximab vedotin; involved-node radiotherapy; sequential relapse
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de Hodgkin
/
Linfoma de Células B
/
Inmunoconjugados
/
Trasplante de Células Madre Hematopoyéticas
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article